Group 1 - Tongda Power achieved a net profit of 42.64 million yuan in the first half of 2025, a year-on-year increase of 32.49% [1] - The company reported an operating income of 971 million yuan, up 22.07% year-on-year [1] - Basic earnings per share were 0.26 yuan [1] Group 2 - Hengshen New Materials reported a net loss of 36.70 million yuan in the first half of 2025, compared to a loss of 10.37 million yuan in the same period last year [2][3] - The company's operating income decreased by 24.84% to 1.22 billion yuan [2] Group 3 - Yiming Pharmaceutical's net profit was 37.56 million yuan, down 5.27% year-on-year [4] - The company experienced an 11.52% decline in operating income, totaling 311 million yuan [4] - Basic earnings per share were 0.20 yuan [4] Group 4 - Wangsu Technology achieved a net profit of 37.30 million yuan, a year-on-year increase of 25.33% [5] - The company's operating income was 2.35 billion yuan, up 2.19% year-on-year [5] - Basic earnings per share were 0.1524 yuan [5] Group 5 - Alloy Investment reported a net profit of 4.58 million yuan, a year-on-year increase of 44.12% [6] - The company achieved an operating income of 164 million yuan, up 73.46% year-on-year [6] - Basic earnings per share were 0.0119 yuan [6] Group 6 - Yifan Pharmaceutical's net profit was 30.40 million yuan, a year-on-year increase of 19.91% [8] - The company's operating income was 2.635 billion yuan, up 0.11% year-on-year [8] - Basic earnings per share were 0.25 yuan [8] Group 7 - Guoyao Yizhi reported a net profit of 66.60 million yuan, a year-on-year decrease of 10.43% [9] - The company's operating income was 36.797 billion yuan, down 2.62% year-on-year [9] - Basic earnings per share were 1.20 yuan [9] Group 8 - Hanjia Design expects a net profit of 15 to 16.5 million yuan, a year-on-year increase of 303.20% to 343.52% [10] - The company anticipates a net profit excluding non-recurring gains and losses of 14.5 to 17.5 million yuan, a year-on-year increase of 867.05% to 1067.13% [10] Group 9 - Gansu Energy Chemical announced the resumption of production at its Jinhe Coal Mine after passing safety inspections [16] Group 10 - Chuanjin Nuo reported a net profit of 177 million yuan, a year-on-year increase of 166.51% [18] - The company's operating income was 1.744 billion yuan, up 27.91% year-on-year [18] - Basic earnings per share were 0.6457 yuan [18] Group 11 - Yachuang Electronics achieved a net profit of 40.82 million yuan, a year-on-year increase of 1.47% [19] - The company's operating income was 2.847 billion yuan, up 125.74% year-on-year [19] - Basic earnings per share were 0.29 yuan [19] Group 12 - Yiheda reported a net profit of 282 million yuan, a year-on-year increase of 26.49% [14] - The company's operating income was 1.461 billion yuan, up 18.70% year-on-year [14] - Basic earnings per share were 0.44 yuan [14] Group 13 - Hatao Technology reported a net profit of 38 million yuan, a year-on-year increase of 233.08% [33] - The company's operating income was 1.475 billion yuan, up 1.12% year-on-year [33] - Basic earnings per share were 0.18 yuan [33] Group 14 - Anlu Technology announced that shareholders plan to reduce their holdings by no more than 3.25% of the company's shares [35] Group 15 - Baolidi reported a net profit of 63.81 million yuan, a year-on-year increase of 15.19% [36] - The company's operating income was 676 million yuan, up 1.47% year-on-year [36] - Basic earnings per share were 0.36 yuan [36] Group 16 - Harta Technology reported a net profit of 33.50 million yuan, a year-on-year increase of 55.61% [38] - The company's operating income was 335 million yuan, up 22.54% year-on-year [38] - Basic earnings per share were 0.0698 yuan [38] Group 17 - Huaxia Biological's controlling shareholder received a loan commitment of up to 250 million yuan from China Merchants Bank [58]

Core Viewpoint - The report highlights the financial performance and operational strategies of Tibet Aim Pharma Co., Ltd. for the first half of 2025, indicating a decline in revenue and net profit while emphasizing the company's focus on maintaining stability and enhancing core product market share amidst industry challenges [2][5][11]. Financial Performance - The company's operating revenue for the first half of 2025 was CNY 311.45 million, a decrease of 11.52% compared to CNY 351.98 million in the same period last year [2][11]. - The net profit attributable to shareholders was CNY 37.56 million, down 5.27% from CNY 39.65 million year-on-year [2][11]. - The net cash flow from operating activities increased by 35.39% to CNY 62.46 million, compared to CNY 46.13 million in the previous year [2][11]. - Total assets at the end of the reporting period reached CNY 1.01 billion, an increase of 8.50% from CNY 926.47 million at the end of the previous year [2][11]. Industry Context - The healthcare reform in China is focusing on building a sustainable medical security system, with a shift from "low price only" to "quality first, reasonable price" in drug procurement policies [5][6]. - The market for chronic disease medications is rapidly growing, particularly in grassroots healthcare settings, with significant increases in spending on cardiovascular and diabetes medications [5][6]. - The company is positioned to benefit from these trends by leveraging its product portfolio and focusing on innovative drug development [5][6]. Business Model and Product Overview - The company's main products are categorized into self-produced drugs and third-party cooperative drugs, with a focus on enhancing market share for core products [5][6][11]. - Key self-produced products include Miglitol tablets, which have a leading market share in the domestic market for Type 2 diabetes medications [8][10]. - The company has successfully participated in multiple rounds of national drug procurement, securing contracts across various provinces [8][10]. Operational Strategies - The company is implementing a "stabilization" strategy to maintain steady operations while enhancing the market presence of its core products [5][11]. - Marketing efforts are centered around target customers, utilizing a multi-channel approach to expand market share and create new profit growth points [6][11]. - Continuous improvements in production management and quality control are being prioritized to ensure product quality and operational efficiency [6][11].

智通财经APP讯，易明医药(002826.SZ)发布2025年半年度报告，报告期内，公司实现营业收入3.11亿 元，同比下降11.52%。实现归属于上市公司股东的净利润3755.71万元，同比下降5.27%。实现归属于上 市公司股东的扣除非经常性损益的净利润2502.22万元，同比增长102.33%。基本每股收益0.2元。 ...

| | | | | 要 | | | --- | --- | --- | --- | --- | --- | | 证券代码：002826 证券简称：易明医药 | | | 公告编号： | | | | 2025-055 | | | | | | | 西藏易明西雅医药科技股份有限公司 2025 年半年度报告摘要 | | | | | | | 一、重要提示 | | | | | | | 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 | | | | | | | 资者应当到证监会 | | | | | | | 指定媒体仔细阅读半年度报告全文。 | | | | | | | 所有董事均已出席了审议本报告的董事会会议。 | | | | | | | 非标准审计意见提示 | | | | | | | □适用 ?不适用 | | | | | | | 董事会审议的报告期利润分配预案或公积金转增股本预案 | | | | | | | □适用 | | | | | ?不适用 | | 公司计划不派发现金红利，不送红股，不以公积金转增股本。 | | | | | | | 董事会决议通过的本报告期优先股利润分配预案 | ...

Group 1 - The third meeting of the board of directors of Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. was held on August 13, 2025, with all 7 directors present, confirming compliance with relevant laws and regulations [1] - The board unanimously approved the 2025 semi-annual report and its summary, affirming that the report accurately reflects the company's actual situation without any false statements or omissions [2] - The company plans to apply for a comprehensive credit limit of up to RMB 100 million from CITIC Bank's Lhasa branch, with an exposure limit of RMB 80 million and a two-year credit term [2]

西藏易明西雅医药科技股份有限公司 二〇二五年半年度财务报告 （未经审计） 西藏易明西雅医药科技股份有限公司 财务报表及附注 （2025 年 06 月 30 日止） 目 录 页 次 财务报表 1-18 合并资产负债表和公司资产负债表 合并利润表和公司利润表 合并现金流量表和公司现金流量表 合并所有者权益变动表和公司所有者权益变动表 财务报表附注 19-104 1、合并资产负债表 编制单位：西藏易明西雅医药科技股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 265,948,740.21 | 427,398,137.38 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 250,000,000.00 | | | 衍生金融资产 | | | | 应收票据 | 91,592.00 | 12,866,464.70 | | 应收账款 | 44,865,565.84 | 39,508,143.20 | | 应收款项融资 | | | | 预付款项 | 2,903 ...

单位：人民币万元 汇总表 | | | 占用方与上市公司 | 上市公司核算的 | 2025 | 年期初占 | 2025 年半年度占 | 2025 年半年度 | 2025 年半 | 2025 年半年度期 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 的关联关系 | 会计科目 | 用资金余额 | | 用累计发生金额 | 占用资金的利息 | 年度偿还累 | 末占用资金余额 | 占用形成原因 | 占用性质 | | | | | | | | （不含利息） | (如有) | 计发生金额 | | | | | 控股股东、实际控制人 | | | | | | | | | | | | | 及其附属企业 | | | | | | | | | | | | | 小计 | - | - | - | | | | | | | - | - | | 前控股股东、实际控制 | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | | 小计 | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 西藏易明西雅医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 13 日召开第三届董事会第二十六次会议，审议通过了《关于公司与业绩承诺方 签订<补偿协议>的议案》，本次补偿相关事项属于公司董事会决策权限，无需提 交股东会审议，现将具体情况公告如下： 一、基本情况概述 1、公司于 2021 年 8 月 13 日召开第二届董事会第二十次会议，审议通过了 《关于公司收购内蒙古博斯泰企业管理服务有限公司 51%股权的议案》，公司以 支付现金的方式收购内蒙古博斯泰企业管理服务有限公司（以下简称"博斯泰" 或"标的公司"）股东王键泽先生持有的该公司 51%股权，交易价格为人民币 3,060.00 万元，双方签订了《股权转让协议》。博斯泰于 2021 年 9 月 2 日完成 工商变更登记工作。 具体内容详见公司在《证券时报》《中国证券报》和巨潮资讯网 （www.cninfo.com.cn）上于 2021 年 8 月 14 日登载的《关于公司收购内蒙古博 斯泰企业管理服务有限公司 51%股权的公告》（公告编号：20 ...

证券代码：002826 证券简称：易明医药 公告编号：2025-053 西藏易明西雅医药科技股份有限公司 关于公司向银行申请综合授信额度的公告 1 西藏易明西雅医药科技股份有限公司 董事会 二〇二五年八月十五日 为满足公司生产经营发展需要，公司拟向中信银行股份有限公司拉萨分行 （以下简称：中信银行）申请不超过人民币 10,000 万元的综合授信额度，其中 敞口额度为人民币 8,000 万元，授信期限两年。该综合授信额度采取信用方式， 无需提供担保，授信种类包括但不限于流动资金贷款、银行承兑汇票、保函、票 据质押、信用证、供应链金融等业务。 以上授信额度为公司可使用的综合授信最高限额，具体使用额度将视公司生 产经营需求决定。授信期限内，授信额度可循环滚动使用。 公司董事会授权董事长在经批准的综合授信额度及有效期内，根据未来业务 实际需求全权办理上述授信事宜，包括但不限于：确定综合授信实际使用额度、 利率等；签署综合授信业务相关的合同文件和其他法律文件；办理综合授信业务 的其他事项。上述事项具体操作由公司资金部负责办理。 本议案在公司董事会决策权限内，无需提交股东大会审议批准。以上授权期 限自本次董事会通过之日起 ...

证券代码：002826 证券简称：易明医药 公告编号：2025-052 西藏易明西雅医药科技股份有限公司 第三届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 西藏易明西雅医药科技股份有限公司（以下简称"公司"或"本公司"）第 三届董事会第二十六次会议已于 2025 年 8 月 13 日在公司会议室以现场与通讯相 结合的方式召开。本次会议于 2025 年 8 月 1 日以电子邮件方式通知了全体董事。 因临时增加了议案，并于 2025 年 8 月 8 日发送了补充通知。 本次会议应到董事 7 人，实到董事 7 人。公司高级管理人员列席了本次会 议。会议由董事长许可先生召集和主持，公司董事会秘书李前进出席并记录了本 次会议。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以 下简称"《公司法》"）等相关法律法规以及《公司章程》的规定。 审议结果：同意 7 票，反对 0 票，弃权 0 票。 为满足公司生产经营发展需要，公司拟向中信银行股份有限公司拉萨分行 （以下简称：中信银行）申请不超过人民币10,0 ...